{"id":"W2521045502","doi":"10.3324/haematol.2016.148924","title":"A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis","year":2016,"lang":"en","type":"article","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; University of Toronto","funders":"National Cancer Institute; Gilead Sciences; European Hematology Association; American Society of Hematology","keywords":"Myelofibrosis; Medicine; Administration (probate law); Phase (matter); Phases of clinical research; Open label; Ruxolitinib; Internal medicine; Adverse effect; Clinical trial; Chemistry; Political science; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001367093,0.001126115,0.002063004,0.0004341617,0.0003384794,0.0006075911,0.0006018772,0.001169008,0.002185751],"category_scores_gemma":[0.0007470834,0.0005316941,0.000853802,0.0002789007,0.0005751838,0.0007089559,0.0002250888,0.002114639,0.0005058935],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004386629,"about_ca_system_score_gemma":0.0008344166,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004023191,"about_ca_topic_score_gemma":0.001141955,"domain_scores_codex":[0.9997101,0.0001267358,0.00001551218,0.00006005909,0.00003331977,0.00005418126],"domain_scores_gemma":[0.9995643,0.00007965284,0.00008263917,0.00003887378,0.00003807884,0.0001962344],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6353773,0.1684587,0.004834377,0.0009636801,0.0009765752,0.0004968151,0.0002294171,0.001718798,0.1032919,0.0002677999,0.003150351,0.08023433],"study_design_scores_gemma":[0.52361,0.4599689,0.008070615,0.00002090763,0.0002367421,0.0002473701,0.00003166612,0.001214201,0.004964524,0.0001496985,0.001457773,0.00002755178],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945879,0.001124576,0.0005483394,0.000216995,0.0001049053,0.002002494,0.0005865673,0.00007447249,0.0007537457],"genre_scores_gemma":[0.9899836,0.001242978,0.002051231,0.0007103599,0.0001909596,0.002644672,0.001335784,0.00002243634,0.001818035],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002185751,"threshold_uncertainty_score":0.007312119,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1801539089104497,"score_gpt":0.4582531616756482,"score_spread":0.2780992527651985,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}